Explore 3 Stock Ideas & Industry Insights Download Free Report

Announcements

JPMorgan Chase Financial Launches $785 Million Uncapped Buffered Digital Notes Linked to European Equity Indices

JPMorgan Chase Financial Company LLC priced $785 million in Uncapped Buffered Digital Notes on July 14, 2026, designed to provide investors with exposure to the EURO STOXX 50 Index and the iShares MSCI EAFE ETF. The structured investment product offers a fixed contingent return …

Aditi Sarkar | 15 July 2026

Bank of Nova Scotia Issues Five-Year Autocallable Notes Linked to Autodesk, Air Products, and Uber Stock Performance

The Bank of Nova Scotia has filed a preliminary pricing supplement for a new class of structured notes offering leveraged upside exposure to the combined performance of three major technology and industrial stocks. The Autocallable Contingent Buffered Return Enhanced Notes, due July 29, 2031, …

Vinay Lochav | 15 July 2026

Nuvalent Acquired by GSK for $124.00 Per Share as Tender Offer Closes and Merger Completes on July 15, 2026

Nuvalent, Inc., the Cambridge, Massachusetts-based biopharmaceutical company traded on the Nasdaq Global Select Market under the ticker NUVL, has been fully acquired by GlaxoSmithKline LLC, a subsidiary of GSK plc, following the successful completion of a cash tender offer and subsequent merger on July …

Manish Choudhary | 15 July 2026

Veradermics Reports Positive Phase 2 Topline Data for VDPHL01 in Female Pattern Hair Loss, Showing Average Hair Count Gains Above 22 Hairs per cm²

Veradermics, Incorporated, a Delaware-incorporated specialty dermatology company listed on the New York Stock Exchange under the ticker MANE, announced on July 15, 2026, that its Phase 2 clinical trial known as Study '207' produced positive topline results for VDPHL01, its proprietary extended-release oral minoxidil …

Manish Choudhary | 15 July 2026

NRG Energy Clears 6,839 MW in PJM Capacity Auction for 2028–2029 Delivery Year at $325 per MW-Day

NRG Energy, Inc. has disclosed that its power plant generation capacity cleared in the PJM Interconnection capacity auction for the 2028–2029 delivery year, with a total of 6,839 megawatts secured at an average clearing price of $325 per MW-day. The announcement, dated July 14, …

Vinay Lochav | 15 July 2026

Cintas Corporation Announces Quarterly Financial Results for the Period Ended May 31, 2026

Cintas Corporation, one of North America's leading providers of corporate identity uniforms and workplace services, disclosed its financial results for the fiscal quarter ended May 31, 2026, via a press release issued on July 15, 2026. The announcement was signed by Scott A. Garula, …

Aditi Sarkar | 15 July 2026

Johnson & Johnson Discloses Second-Quarter and Six-Month Sales and Earnings Results for Period Ended June 28, 2026

Johnson & Johnson, the diversified healthcare giant headquartered in New Brunswick, New Jersey, announced its sales and earnings results for the second quarter ended June 28, 2026, in a disclosure dated July 15, 2026. The announcement, signed by Controller Robert J. Decker, Jr. as …

Anjali Anand | 15 July 2026

Conagra Brands Reports Fourth Quarter Fiscal 2026 Financial Results

Conagra Brands, Inc., the Chicago-based packaged food company behind well-known consumer brands, disclosed its fourth quarter fiscal 2026 financial results on July 15, 2026, through a press release issued the same day. The announcement represents the company's final quarterly earnings update for fiscal year …

Vinay Lochav | 15 July 2026

Entegris Declares $0.10 Quarterly Cash Dividend Payable August 19, 2026

Entegris, Inc., the Billerica, Massachusetts-based semiconductor materials and solutions company, has announced that its board of directors declared a quarterly cash dividend of $0.10 per share, according to a disclosure filed on July 15, 2026. The dividend is scheduled to be paid on August …

Nitish Kishor | 15 July 2026

FDA Accepts Axsome Therapeutics' New Drug Application for AXS-12 (Reboxetine) to Treat Cataplexy in Narcolepsy

Axsome Therapeutics, Inc. has announced that the U.S. Food and Drug Administration has accepted for filing the company's New Drug Application for AXS-12 (reboxetine), a candidate being developed for the treatment of cataplexy in patients with narcolepsy. The announcement, made on July 15, 2026, …

Vinay Lochav | 15 July 2026
Support

Hi! How can we help you today?

Loading…